			Sheet 1 of 1
U.S. DEPARTMENT OF COMMERCE	TY. DOCKET NO.	OIPE	SERIAL NO.
PATENT AND TRADEMARK OFFICE	201487/1070 (KUV-101PCT-US)	440	09/937,739
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT	AU6 0 6 2002	
	Amagai et al.	The second second	
(use several sheets if necessary)	FILING DATE	TRADEMAN	GROUP ART UNIT
(PTO-1449)	March 30, 2000		1632

# U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
-				RECE	IVED	
				AUG 0	9 2002	
				TECH CENTE	R 1600/2900	

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
$\square$	1	Amagai et al., "Use of Autoantigen-Knockout Mice in Developing an Active Autoimmune Disease Model for Pemphigus,"
		J. Clin. Invest., 105(5):625-631 (2000)
1	2	Fan et al., "BALB/c Mice Produce Blister-Causing Antibodies Upon Immunization with a Recombinant Human Desmoglein 3 <sup>1</sup> ,"
		J. Immunol., 163:6228-6235 (1999)
	3	Ono et al., Igaku no Ayumi, pp. 282-284 (1995) (abstract)
A	4	Amagai et al., "Desmoglein 3 (Pemphigus vulgaris Antigen) as a Major Autoimmune Target in Paraneoplastic Pemphigus and
		Its Role in Pathogenesis," J. Invest. Dermatol., 110:482 (1998) (abstract)
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			Sheet 1.0f2
U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.	НЭ
PATENT AND TRADEMARK OFFICE	201487/1070	09/937,739	SE WA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT MAY 0 0		NTE Y
	Amagai et al.		
(use several sheets if necessary)	FILING DATE	GROUP ART UNIT	2002 600/29
(PTO-1449)	March 30, 2000	1632	290

# U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

# OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

8/	1	Koch et al., "Targeted Disruption of the Pemphigus Vulgaris Antigen (Desmoglein 3) Gene in Mice Causes Loss of Keratinocyte					
0		Cell Adhesion with a Phenotype Similar to Pemphigus Vulgaris," J. Cell Biology, 137(5):1091-1102 (1997)					
	2	Juhasz et al., "Development of Pemphigus Vulgaris-Like Lesions in Severe Combined Immunodeficiency Disease Mice					
f = f	ŀ	Reconstituted with Lymphocytes from Patients," <u>J. Clin. Invest.</u> , 92:2401-2407 (1993)					
1	3	Stanley, "Cell Adhesion Molecules as Targets of Autoantibodies in Pemphigus and Pemphigoid, Bullous Diseases Due to					
1)		Defective Epidermal Cell Adhesion," Adv. Immunol., 53:291-325 (1993)					
	4	Goodnow, "Balancing Immunity and Tolerance: Deleting and Tuning Lymphocyte Repertoires," Proc. Natl. Acad. Sci. USA,					
		93:2264-2271 (1996)					
	5	MacDonald, "Mechanisms of Immunological Tolerance," Science, 246:982 (1989)					
1							
-	6	Bach et al., "Are There Unique Autoantigens Triggering Autoimmune Diseases?" Immunol. Rev., 164:139-155 (1998)					
	7	Hashimoto et al., "Anti-Cell Surface Pemphigus Autoantibody Stimulates Plasminogen Activator Activity of Human Epidermal					
		Cells," J. Exp. Med., 157:259-272 (1983)					
	8	Anhalt et al., "Induction of Pemphigus in Neonatal Mice by Passive Transfer of IgG From Patients with the Disease,"					
		N. Engl. J. Med., 306:1189-1196 (1982)					
	9	Schulz et al., "Development of CD4 CD8 αβTCR NK1.1 T Lymphocytes," J. Immunol., 157:4379-4389 (1996)					
١ .							
8	10	Koch et al., "Desmoglein 3 Anchors Telogen Hair in the Follicle," J. Cell Sci., 111:2529-2537 (1998)					
EXAMINER		DATE CONSIDERED					
	(	3/11/03					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

#### OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

$\mathcal{Y}$	11	Schiltz et al., "Production of Epidermal Acantholysis in Normal Human Skin In Vitro by the IgG Fraction From Pemphigus
/		Serum," J. Invest. Dermatol., 67:254-260 (1976)
)	12	Ishii et al., "Characterization of Autoantibodies in Pemphigus Using Antigen-Specific Enzyme-Linked Immunosorbent Assays
1		With Baculovirus-Expressed Recombinant Desmogleins," J. Immunol., 159:2010-2017 (1997)
	13	Amagai et al., "Antigen-Specific Immunoadsorption of Pathogenic Autoantibodies in Pemphigus Foliaceus," J. Invest. Dermatol
		104:895-901 (1995)
	14	Amagai, "Pemphigus: Autoimmunity to Epidermal Cell Adhesion Molecules," <u>Adv. Dermatol.</u> , 11:319-352 (1996)
	15	Amagai et al., "Autoantibodies Against a Novel Epithelial Cadherin in Pemphigus Vulgaris, a Disease of Cell Adhesion,"
	į	<u>Cell</u> , 67:869-877 (1991)
	16	Amagai et al., "Antibodies Against Desmoglein 3 (Pemphigus Vulgaris Antigen) Are Present in Sera from Patients With
[ ]		Paraneoplastic Pemphigus and Cause Acantholysis In Vivo in Neonatal Mice," J. Clin. Invest., 102:775-782 (1998)
	17	Amagai et al., "Usefulness of Enzyme-Linked Immunosorbent Assay Using Recombinant Desmogleins 1 and 3 for Serodiagnos
		of Pemphigus," Br. J. Dermatol., 140:351-357 (1999)
	18	Dry, "The Coat of the Mouse (Mus musculus)," in Bateson, eds., Journal of Genetics, Vol. XVI. (1926), London: Wm. Dawson &
		Sons Ltd., pp. 287-340 (reprinted 1963)
	19	Amagai et al., "Absorption of Pathogenic Autoantibodies by the Extracellular Domain of Pemphigus Vulgaris Antigen (Dsg3)
1		Produced by Baculovirus," J. Clin. Invest., 94:59-67 (1994)
0	20	Amagai et al., "Autoantibodies Against the Amino-Terminal Cadherin-Like Binding Domain of Pemphigus Vulgaris Antigen
*		are Pathogenic," J. Clin. Invest., 90:919-926 (1992)

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.